EP1901071A4 - Methods of diagnosing, preventing and treating infection with hepatitis c virus - Google Patents
Methods of diagnosing, preventing and treating infection with hepatitis c virusInfo
- Publication number
- EP1901071A4 EP1901071A4 EP06756917A EP06756917A EP1901071A4 EP 1901071 A4 EP1901071 A4 EP 1901071A4 EP 06756917 A EP06756917 A EP 06756917A EP 06756917 A EP06756917 A EP 06756917A EP 1901071 A4 EP1901071 A4 EP 1901071A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- hepatitis
- diagnosing
- virus
- preventing
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000711549 Hepacivirus C Species 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
- C07K16/109—Hepatitis C virus; Hepatitis G virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005162557 | 2005-06-02 | ||
PCT/JP2006/311082 WO2006129786A1 (en) | 2005-06-02 | 2006-06-02 | Methods of diagnosing, preventing and treating infection with hepatitis c virus |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1901071A1 EP1901071A1 (en) | 2008-03-19 |
EP1901071A4 true EP1901071A4 (en) | 2008-10-22 |
EP1901071B1 EP1901071B1 (en) | 2010-03-10 |
Family
ID=37481713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06756917A Not-in-force EP1901071B1 (en) | 2005-06-02 | 2006-06-02 | Methods for screening an anti-hepatitis c virus candidate |
Country Status (5)
Country | Link |
---|---|
US (1) | US20090136515A1 (en) |
EP (1) | EP1901071B1 (en) |
JP (1) | JP4958773B2 (en) |
DE (1) | DE602006012836D1 (en) |
WO (1) | WO2006129786A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101239541B1 (en) * | 2007-07-02 | 2013-03-06 | 아사히 가세이 메디컬 가부시키가이샤 | Therapeutic agent for ulcerative colitis comprising mizoribine |
US9487837B2 (en) | 2008-10-06 | 2016-11-08 | Morehouse School Of Medicine | Exosome-mediated diagnosis of hepatitis virus infections and diseases |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000026418A1 (en) * | 1998-11-05 | 2000-05-11 | The Board Of Trustees Of Leland Stanford Junior University | Human pan-hcv human monoclonal antibodies |
WO2002062956A2 (en) * | 2001-02-02 | 2002-08-15 | Chemocentryx, Inc. | Chemomagnetic retrieval of cmv and cmv infected cells |
WO2002100900A2 (en) * | 2001-06-13 | 2002-12-19 | Biostrands S.R.L. | Human recombinant antibody against the hepatitis c (hcv) non structural ns3 protein, nucleic acid and uses thereof |
WO2004013318A1 (en) * | 2002-08-06 | 2004-02-12 | Mcgill University | Method for inducing complete hepatitis c virus (hcv) replication in vitro |
-
2006
- 2006-06-02 DE DE602006012836T patent/DE602006012836D1/en active Active
- 2006-06-02 US US11/921,285 patent/US20090136515A1/en not_active Abandoned
- 2006-06-02 WO PCT/JP2006/311082 patent/WO2006129786A1/en active Application Filing
- 2006-06-02 EP EP06756917A patent/EP1901071B1/en not_active Not-in-force
- 2006-06-02 JP JP2007519081A patent/JP4958773B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000026418A1 (en) * | 1998-11-05 | 2000-05-11 | The Board Of Trustees Of Leland Stanford Junior University | Human pan-hcv human monoclonal antibodies |
WO2002062956A2 (en) * | 2001-02-02 | 2002-08-15 | Chemocentryx, Inc. | Chemomagnetic retrieval of cmv and cmv infected cells |
WO2002100900A2 (en) * | 2001-06-13 | 2002-12-19 | Biostrands S.R.L. | Human recombinant antibody against the hepatitis c (hcv) non structural ns3 protein, nucleic acid and uses thereof |
WO2004013318A1 (en) * | 2002-08-06 | 2004-02-12 | Mcgill University | Method for inducing complete hepatitis c virus (hcv) replication in vitro |
Non-Patent Citations (4)
Title |
---|
ESPOSITO G ET AL: "RECOMBINANT HUMAN ANTIBODIES SPECIFIC FOR HEPATITIS C VIRUS PROTEINS", ARCHIVES OF VIROLOGY, NEW YORK, NY, US, vol. 142, no. 3, 1 January 1997 (1997-01-01), pages 601 - 610, XP001148378, ISSN: 0304-8608 * |
HEINTGES TOBIAS ET AL: "Characterization and binding of intracellular antibody fragments to the hepatitis C virus core protein", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 263, no. 2, 24 September 1999 (1999-09-24), pages 410 - 418, XP002492589, ISSN: 0006-291X * |
SANSONNO D ET AL: "Detection of Hepatitis C Viurs(HCV) proteins by immunofluorescence and HCV RNA genomic sequences by non-isotopic in situ hybridization in bone marrow and peripheral blood mononuclear cells of chronically HCV-infected patients", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, OXFORD, GB, vol. 103, 1 January 1996 (1996-01-01), pages 414 - 421, XP003002676, ISSN: 0009-9104 * |
See also references of WO2006129786A1 * |
Also Published As
Publication number | Publication date |
---|---|
DE602006012836D1 (en) | 2010-04-22 |
EP1901071B1 (en) | 2010-03-10 |
JPWO2006129786A1 (en) | 2009-01-08 |
WO2006129786A1 (en) | 2006-12-07 |
EP1901071A1 (en) | 2008-03-19 |
JP4958773B2 (en) | 2012-06-20 |
US20090136515A1 (en) | 2009-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL189329A (en) | Vaccination against dengue virus infection, kit and use of same | |
EP2177535A4 (en) | Antibody having inhibitory activity on infection with hepatitis c virus (hcv), and use thereof | |
EP1863941A4 (en) | Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof | |
AP2406A (en) | Macrocydic inhibitors of hepatitis C virus. | |
AP2313A (en) | Inhibitors of hepatitis C virus RNA-dependent RNA ploymerase, and compositions and treatments using the same. | |
IL200432A (en) | Human antibodies against hepatitis c virus (hcv) and uses thereof | |
TWI347184B (en) | Methods of treating hiv infection | |
WO2007092888A3 (en) | Hcv ns5b inhibitors | |
IL194920A0 (en) | Hepatitis c virus infection biomarkers | |
WO2007140200A3 (en) | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors | |
WO2010030538A3 (en) | Compounds for the treatment of hepatitis c | |
EP1954788A4 (en) | Combustion catalyst carriers and methods of using the same | |
GB0718984D0 (en) | Structure of the hepatitis C virus NS5A protein | |
PL2083811T3 (en) | Methods of treating down's syndrome, fragile x syndrome and autism | |
EP1723238A4 (en) | Modified oncolytic viruses | |
WO2009029384A3 (en) | Compounds for the treatment of hepatitis c | |
EP1765330A4 (en) | Pyranoindole derivatives and the use thereof for the treatment of hepatitis c virus infection or disease | |
ZA200703157B (en) | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection | |
IL178492A0 (en) | Cancer treatment using viruses and camptothecins | |
EP2120988A4 (en) | Treating hepatitis c virus infection | |
HK1109069A1 (en) | Vaccine composition against hepatitis c virus | |
GB0416487D0 (en) | Modified virus | |
GB2441094B (en) | Methods for treatment and prevention of infection | |
EP1901071A4 (en) | Methods of diagnosing, preventing and treating infection with hepatitis c virus | |
IL187160A0 (en) | Compositions and methods for treating hiv infection with cupredoxin and cytochrome c |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20071213 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20080919 |
|
17Q | First examination report despatched |
Effective date: 20090202 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RTI1 | Title (correction) |
Free format text: METHODS FOR SCREENING AN ANTI-HEPATITIS C VIRUS CANDIDATE |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 602006012836 Country of ref document: DE Date of ref document: 20100422 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: SERVOPATENT GMBH |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20100310 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100310 |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20100310 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100310 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100310 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100310 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100310 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100310 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100310 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100611 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100621 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100310 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100310 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100310 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100310 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100310 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100310 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100310 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100710 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100610 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100310 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100712 Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100630 |
|
26N | No opposition filed |
Effective date: 20101213 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20110228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100310 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100602 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100911 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100602 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100310 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20180619 Year of fee payment: 13 Ref country code: CH Payment date: 20180629 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20180620 Year of fee payment: 13 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602006012836 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20190602 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200101 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190602 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190630 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190630 |